With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore ...

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off them.

GLP-1 drugs like Ozempic and Wegovy can help most people lose weight, but they don’t work for everyone. Here are 5 common ...

The North Carolina state treasurer is taking on drugmakers Novo Nordisk and Eli Lilly in an attempt to lower drug costs for ...

Medicare Part D, which provides prescription drug coverage, will now cover the weight-loss medication Wegovy in cases where ...

Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of ...

Congressional leaders and the administration must work together to expand access to anti-obesity medications through Medicare ...

Less than half of large employers currently cover the new generation of obesity drugs, but an additional 18% say they’re considering adding them amid surging interest. Nov. 11, 2023 In some ...

LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. The ...

“It’s not all about weight loss,” he said, adding that semaglutide ... and often linked with obesity. The growing list of potential uses for obesity drugs has been driving up expectations ...

Ozempic and weight-loss drugs raise hopes for obesity, but complexities exist. The Ozempic buzz plays into ideas of fat stigma and fatphobia. The Ozempic doesn't work same for everyone.

A budget-busting 3.6 million Medicare recipients could now be eligible for coverage of the weight-loss drug Wegovy, a new KFF ...